{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T22:36:13Z","timestamp":1765233373909,"version":"build-2065373602"},"reference-count":75,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA206963"],"award-info":[{"award-number":["CA206963"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008884","name":"Edward P. Evans Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014926","name":"Acceleron","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014926","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.clml.2022.07.012","type":"journal-article","created":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T17:39:43Z","timestamp":1658597983000},"page":"869-877","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["SOHO State of the Art and Next Questions: Treatment of Higher-Risk Myelodysplastic Syndromes"],"prefix":"10.1016","volume":"22","author":[{"given":"Brandon J.","family":"Aubrey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.07.012_bib0001","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4065\/81.1.104","article-title":"The myelodysplastic syndromes: diagnosis and treatment","volume":"81","author":"Steensma","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2022.07.012_bib0002","doi-asserted-by":"crossref","first-page":"106","DOI":"10.6004\/jnccn.2022.0009","article-title":"NCCN Guidelines(R) Insights: Myelodysplastic Syndromes, Version 3.2022","volume":"20","author":"Greenberg","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2022.07.012_bib0003","first-page":"1286","article-title":"Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology","volume":"87","author":"Alessandrino","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.07.012_bib0004","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1365-2141.2003.03907.x","article-title":"Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes","volume":"120","author":"Bowen","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.07.012_bib0005","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.012_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clml.2021.07.031","article-title":"Myelodysplastic Syndromes: A New Decade","volume":"22","author":"Volpe","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.07.012_bib0007","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.012_bib0008","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.012_bib0009","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1200\/JCO.2012.48.0764","volume":"31","author":"Voso","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.012_bib0010","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/leu.2015.55","volume":"29","author":"Della Porta","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.07.012_bib0011","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2006.08.5696","article-title":"Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes","volume":"25","author":"Malcovati","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.012_bib0012","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2010.31.3353","article-title":"Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model","volume":"29","author":"Naqvi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.012_bib0013","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3324\/haematol.2010.033506","article-title":"Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome","volume":"96","author":"Della Porta","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.07.012_bib0014","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/bjh.14033","article-title":"Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study","volume":"174","author":"Buckstein","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.07.012_bib0015","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood.V120.21.311.311","article-title":"Detection of recurrent mutations by pooled targeted next-generation sequencing in MDS patients prior to treatment with hypomethylating agents or stem cell transplantation","volume":"120","author":"Bejar","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.012_bib0016","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.leukres.2012.08.009","article-title":"Molecular genetics in myelodysplastic syndromes","volume":"36","author":"Haferlach","year":"2012","journal-title":"Leuk Res"},{"year":"2021","series-title":"Molecular international prognosis scoring system for myelodysplastic syndromes","author":"Bernard","key":"10.1016\/j.clml.2022.07.012_bib0017"},{"key":"10.1016\/j.clml.2022.07.012_bib0018","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s11899-017-0407-9","article-title":"Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS","volume":"12","author":"Nazha","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2022.07.012_bib0019","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/bloodadvances.2018026989","article-title":"NPM1 mutations define a specific subgroup of MDS and MDS\/MPN patients with favorable outcomes with intensive chemotherapy","volume":"3","author":"Montalban-Bravo","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.07.012_bib0020","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2021011304","article-title":"Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal","volume":"139","author":"Estey","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.012_bib0021","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.bbmt.2013.06.008","article-title":"Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies","volume":"19","author":"Brunner","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2022.07.012_bib0022","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.012_bib0023","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jtct.2021.02.031","article-title":"Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial","volume":"27","author":"Scott","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2022.07.012_bib0024","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1200\/JCO.2016.70.7349","article-title":"Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)","volume":"35","author":"Kroger","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.012_bib0025","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","article-title":"A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome","volume":"104","author":"Cutler","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.012_bib0026","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1200\/JCO.2012.46.8652","article-title":"Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis","volume":"31","author":"Koreth","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.012_bib0027","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2020-136828","volume":"136","author":"Nakamura","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.012_bib0028","article-title":"IMPACT OF CONDITIONING INTENSITY AND GENOMICS ON RELAPSE AFTER ALLOGENEIC TRANSPLANTATION FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME","author":"Dillon","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.clml.2022.07.012_bib0029","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1804714","article-title":"Mutation Clearance after Transplantation for Myelodysplastic Syndrome","volume":"379","author":"Duncavage","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.07.012_bib0030","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.012_bib0031","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.07.012_bib0032","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1182\/blood-2017-10-811729","article-title":"Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation","volume":"131","author":"Zeidan","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.012_bib0033","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.2019004143","article-title":"Oral cedazuridine\/decitabine for MDS and CMML: a phase 2 pharmacokinetic\/pharmacodynamic randomized crossover study","volume":"136","author":"Garcia-Manero","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.012_bib0034","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2015.66.2510","article-title":"Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117","volume":"35","author":"Sekeres","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.012_bib0035","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood-2018-99-111756","article-title":"A Randomized Phase II Study of Azacitidine (AZA) Alone or with Lenalidomide (LEN), Valproic Acid (VPA) or Idarubicin (IDA) in Higher-Risk MDS: Gfm's \u2018pick a Winner'Trial","volume":"132","author":"Ades","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.012_bib0036","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","article-title":"Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure","volume":"29","author":"Prebet","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.012_bib0037","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1470-2045(16)00009-7","article-title":"Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial","volume":"17","author":"Garcia-Manero","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.07.012_bib0038","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.cell.2017.11.035","article-title":"On the Design of Combination Cancer Therapy","volume":"171","author":"Doroshow","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.clml.2022.07.012_bib0039","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrc.2016.112","article-title":"The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia","volume":"17","author":"Sperling","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2022.07.012_bib0040","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.2016.71.0806","article-title":"Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome","volume":"35","author":"Kennedy","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.012_bib0041","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1182\/blood-2019-123946","article-title":"Ivosidenib (AG-120) in patients with IDH1-mutant relapsed\/refractory myelodysplastic syndrome: Updated enrollment of a phase 1 dose escalation and expansion study","volume":"134","author":"Foran","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.012_bib0042","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1016\/S2352-3026(19)30284-4","article-title":"Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial","volume":"7","author":"Stein","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2022.07.012_bib0043","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.07.012_bib0044","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood.V96.12.3932","article-title":"The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS","volume":"96","author":"Parker","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.012_bib0045","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/leu.2015.179","article-title":"Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients","volume":"30","author":"Jilg","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.07.012_bib0046","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/leu.2014.44","article-title":"BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies","volume":"28","author":"Bogenberger","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.07.012_bib0047","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood-2020-139492","article-title":"Safety, efficacy, and patient-reported outcomes of venetoclax in combination with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome: A phase 1b study","volume":"136","author":"Garcia","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.012_bib0048","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1182\/blood-2019-124437","article-title":"A phase 1b study evaluating the safety and efficacy of venetoclax in combination with azacitidine in treatment-na\u00efve patients with higher-risk myelodysplastic syndrome","volume":"134","author":"Wei","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.012_bib0049","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1182\/blood-2019-124994","article-title":"A phase 1b study evaluating the safety and efficacy of venetoclax as monotherapy or in combination with azacitidine for the treatment of relapsed\/refractory myelodysplastic syndrome","volume":"134","author":"Zeidan","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.012_bib0050","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1182\/bloodadvances.2020001482","article-title":"Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure","volume":"4","author":"Ball","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.07.012_bib0051","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood-2021-151137","article-title":"A Pilot Study of CPX-351 (Vyxeos\u00a9) for Transplant Eligible, Higher Risk Patients with Myelodysplastic Syndrome","volume":"138","author":"Jacoby","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.012_bib0052","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2012-05-430736","article-title":"Inhibition of apoptosis by BCL2 prevents leukemic transformation of a murine myelodysplastic syndrome","volume":"120","author":"Slape","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.012_bib0053","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2021-145646","article-title":"Venetoclax and Azacitidine in the Treatment of Patients with Relapsed\/Refractory Myelodysplastic Syndrome","volume":"138","author":"Zeidan","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.012_bib0054","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1182\/blood-2021-146634","article-title":"Assessing the Role of Venetoclax in Combination with Hypomethylating Agents in Higher Risk Myelodysplastic Syndromes","volume":"138","author":"Komrokji","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.012_bib0055","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.012_bib0056","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1080\/10428194.2016.1266625","article-title":"The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications","volume":"58","author":"Zhang","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.07.012_bib0057","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.07.012_bib0058","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm0302-282","article-title":"Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound","volume":"8","author":"Bykov","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2022.07.012_bib0059","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1200\/JCO.2011.40.7783","article-title":"Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer","volume":"30","author":"Lehmann","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.012_bib0060","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1182\/blood-2018-99-119990","article-title":"Phase 1b\/2 combination study of APR-246 and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)","volume":"132","author":"Sallman","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.012_bib0061","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201544","article-title":"Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS","volume":"218","author":"Trowbridge","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.clml.2022.07.012_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2021.100824","article-title":"Emerging immuno-oncology targets in Myelodysplastic Syndromes (MDS)","volume":"46","author":"Mann","year":"2022","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.clml.2022.07.012_bib0063","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for Patients with Relapse after Allogeneic Transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.07.012_bib0064","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1182\/bloodadvances.2021005240","article-title":"Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome","volume":"6","author":"Gerds","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.07.012_bib0065","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/bjh.17689","article-title":"Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome","volume":"195","author":"Chien","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.07.012_bib0066","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2020-141100","article-title":"Final Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agent Therapy","volume":"136","author":"Chien","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.012_bib0067","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2020-140521","article-title":"Updated Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Previously-Untreated Patients with Higher-Risk Myelodysplastic Syndrome","volume":"136","author":"Chien","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.012_bib0068","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1182\/blood-2018-99-118948","article-title":"Double immune checkpoint inhibitor blockade with nivolumab and ipilimumab with or without azacitidine in patients with myelodysplastic syndrome (MDS)","volume":"132","author":"Garcia-Manero","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.012_bib0069","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1158\/1078-0432.CCR-17-3763","article-title":"A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent FailurePhase I Study of Ipilimumab in Patients with MDS Post-HMA Failure","volume":"24","author":"Zeidan","year":"2018","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.clml.2022.07.012_bib0070","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood.V126.23.1666.1666","article-title":"Stabilization of myelodysplastic syndromes (MDS) following hypomethylating agent (HMAs) failure using the immune checkpoint inhibitor ipilimumab: a phase I trial","volume":"126","author":"Zeidan","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.012_bib0071","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2020-142003","article-title":"A phase II study of double immune checkpoint inhibitor blockade with nivolumab and ipilimumab with or without azacitidine in patients with myelodysplastic syndrome (MDS)","volume":"136","author":"Morita","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.012_bib0072","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2020-136235","article-title":"Safety and efficacy of decitabine plus ipilimumab in relapsed or refractory MDS\/AML in the post-BMT or transplant na\u00efve settings","volume":"136","author":"Garcia","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.012_bib0073","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2018-99-119424","article-title":"A phase II study of nivolumab or ipilimumab with or without azacitidine for patients with myelodysplastic syndrome (MDS)","volume":"132","author":"Garcia-Manero","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.012_bib0074","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/bjh.13323","article-title":"Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study","volume":"169","author":"Swords","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.07.012_bib0075","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1038\/s41375-021-01125-4","article-title":"Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS\/CMML or low-blast AML","volume":"35","author":"Sekeres","year":"2021","journal-title":"Leukemia"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022002324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022002324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:40:21Z","timestamp":1761871221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022002324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":75,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2152265022002324"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.07.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art and Next Questions: Treatment of Higher-Risk Myelodysplastic Syndromes","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}